Episode

How Quantum Computing Is Becoming a Drug Pricing Tool for Pharma

Podcast
Quantum Computing Business with Fexingo: Hardware, Software, and Enterprise Quantum
Published
Jun 13, 2026
Duration seconds
540
Processing state
not_requested
Canonical source
https://audio.fexingo.com/business/quantum-computing-business/episode-0048.mp3
Audio
https://audio.fexingo.com/business/quantum-computing-business/episode-0048.mp3
JSON
/v1/public/podcasts/quantum-computing-business-with-fexingo-hardware-software-and-enterprise-quantum-7872009/episodes/how-quantum-computing-is-becoming-a-drug-pricing-tool-for-pharma
Markdown
/podcast/quantum-computing-business-with-fexingo-hardware-software-and-enterprise-quantum-7872009/how-quantum-computing-is-becoming-a-drug-pricing-tool-for-pharma.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/quantum-computing-business-with-fexingo-hardware-software-and-enterprise-quantum-7872009/episodes/how-quantum-computing-is-becoming-a-drug-pricing-tool-for-pharma/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/quantum-computing-business-with-fexingo-hardware-software-and-enterprise-quantum-7872009/how-quantum-computing-is-becoming-a-drug-pricing-tool-for-pharma.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Episode 48 of Quantum Computing Business with Fexingo explores a surprising new frontier: using quantum algorithms to model drug pricing under uncertainty. Lucas and Luna examine how pharma companies are beginning to apply quantum Monte Carlo simulations to forecast optimal launch prices for new drugs, factoring in clinical trial risks, competitor pipelines, and payer negotiations. They dig into a concrete case: a mid-stage biotech using a hybrid quantum-classical platform from a startup called Qubit Pharmaceuticals to set pricing for a rare-disease therapy. The hosts walk through why traditional spreadsheets fall short, how quantum methods handle thousands of correlated variables, and what the FDA's recent guidance on real-world evidence means for quantum-powered pricing models. They also discuss the broader implications—could this shift accelerate drug access, or will it concentrate pricing power among early adopters? #QuantumComputing #DrugPricing #Pharma #PricingStrategy #MonteCarlo #QubitPharmaceuticals #RareDisease #FDA #RealWorldEvidence #Biotech #PayerNegotiations #ClinicalTrials #HybridQuantum #QuantumAlgorithms #HealthcareEconomics #Business #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo